RNXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RenovoRx Inc (RNXT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising technology and a positive analyst rating, the technical indicators are bearish, recent financial performance shows mixed results, and there are no strong catalysts or trading signals to suggest immediate upside potential.
The technical indicators for RNXT are bearish. The MACD is negatively expanding, RSI is neutral at 50.329, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.969, with resistance at 1.057 and support at 0.882.
The company has an FDA-cleared dual-balloon catheter, RenovoCath, which is particularly useful for treating pancreatic cancer. Analyst Justin Walsh has initiated coverage with a Buy rating and an $8 price target, indicating long-term potential.
No significant news or trading trends from hedge funds or insiders. Technical indicators are bearish, and there is no recent congress trading data or strong trading signals.
In Q4 2025, revenue increased significantly by 453.49% YoY to $238,000, but net income remains negative at -$2,941,000, improving only slightly by 2.19% YoY. EPS dropped by 60% YoY to -0.08, and gross margin declined to 88.24%, down 11.76% YoY. The financials indicate growth in revenue but ongoing profitability challenges.
Analyst Justin Walsh from JonesResearch has initiated coverage with a Buy rating and an $8 price target, citing the potential of the company's medical technology.
